High hospital readmission rates with PAD ‘potentially avoidable’
The extent of post-discharge complications has been revealed in the first detailed analysis of Australian data for this group of patients.
Tag: Peripheral artery disease (PAD)
Rivaroxaban ‘beneficial’ after revascularisation for claudication
Further results from the VOYAGER-PAD trial show use of the agent reduces major cardiovascular events.
Patients with peripheral artery disease ‘underestimate walking progress’
Self-reported improvement after exercise programs tends to fall short of objective data, researchers say.
PAD: Doubt on harm linked to drug-coated stents
New ‘robust’ research failed to replicate earlier findings signalling an increased mortality risk, conference told.
Adding a NOAC to aspirin ‘reduces events after revascularisation’
New results from the VOYAGER PAD trial shows a benefit with no increase in bleeds.
Which treatment is best for intermittent claudication?
Australian doctors have carried out a network meta-analysis to compare four different approaches to therapy.
Combination therapy ‘reduces risk of vascular events’ in PAD
A secondary trial analysis shows low-dose rivaroxaban and aspirin benefit high-risk patients with lower extremity PAD, authors say.
Time to rethink ‘no pain, no gain’ for patients with peripheral artery disease
It might be worth prescribing other forms of exercise, such as resistance training: researchers.
